Ulrich Thienel, MD, PhD

Ulrich Thienel

Chief Executive Officer / Director

Ulrich Thienel, MD, PhD is the Chief Executive Officer of ReAlta and provides strategic leadership for commercialization of ReAlta’s new class of Complement and Inflammation Inhibition drug products for a variety of life-threatening medical conditions. Ulrich was formerly Chief Medical Officer at Finch Therapeutics, Boston. Prior to Finch, Ulrich had 20 years of biopharmaceutical drug development leadership, with experience in both biotech and large pharma, including Johnson & Johnson, BMS, and Takeda. His experience spans autoimmune, hematology, neuroscience, respiratory and rare diseases. In previous roles as Therapeutic Area Leader and Chief of Development and Medical Officer, he oversaw research development and commercialization of multiple assets, including small molecules, siRNA, antibody and device technologies. He is well versed in FDA regulatory processes, including experience with multiple Investigational New Drugs (INDs), New Drug Applications (NDAs) and Biologics License Applications (BLAs). Ulrich received his MD and PhD degrees at Justus-Liebig University in Giessen, Germany and also completed training in Internal Medicine. He subsequently completed specialty training in Rheumatology at Columbia University in New York and Executive Training in Sales and Marketing at Northwestern University in Chicago.

Back to Team